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of the ethnic categories. Only 15.6% and 9.7% of the patients
had lipid tests and LFTs within three months since the start 
of therapy. Non-Hispanic blacks were less likely to have lipid
tests compared to non-Hispanic whites (OR = 0.804; 95% CI,
0.653–0.990). Presence of coronary heart disease (OR = 1.305;
95% CI, 1.093–1.556) and lipid test prior to the start of therapy
(OR = 4.207; 95% CI, 3.607–4.908) were associated with an
increased likelihood of lipid tests after the start of therapy. Older
patients (OR = 0.987; 95% CI, 0.977–0.997) and non-Hispanic
blacks (OR = 0.543; 95% CI, 0.413–0.713) had a lower likeli-
hood of having LFTs than younger patients and whites. Presence
of hypertension (OR = 1.312; 95% CI, 1.081–1.592) and prior
LFTs (OR = 3.561; 95% CI, 2.939–4.315) were associated with
an increased likelihood of LFTs after the start of therapy. CON-
CLUSION: Monitoring of lipid levels and adverse events for
patients on statin therapy remains suboptimal. There exists an
ethnic disparity in the management of hyperlipidemia.
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OBJECTIVES: To examine effect of co-payment on the initia-
tion of statins after coronary heart disease (CHD) hospitali-
zation. METHODS: Medstat Marketscan commercial and
Medicare 1999–2002 databases including inpatient admission,
outpatient and pharmacy claims were utilized for this study. The
ﬁrst CHD hospital admission was identiﬁed as the index hospi-
talization. The study sample consisted of adults who had no
statin use during the year prior to the index hospitalization and
had at least six-month follow up after discharge. The outcome
was the initiation of any statin prescription during six-month
follow up. Effect of co-payment on the initiation of statins was
examined by a multiple logistic regression, controlling for age,
gender, region, year of the index hospitalization, length of 
stay, baseline comorbidity, baseline number of drug therapeutic
classes, and baseline non-statin lipid-lowering drug use.
RESULTS: A total of 12,182 subjects met the inclusion criteria
and were included in the analysis. Only 5411 (44.41%) had ini-
tiated statin therapy within six-months after discharge. Com-
pared with those who had a co-payment less than or equal to
$10, subjects with a co-payment over $20 were about two thirds
less likely to initiate statin therapy (OR, 0.34; 95% CI,
0.29–0.39), while subjects with a co-payment between $10 to
$20 were about 14% less likely. (OR: 0.86; 95% CI, 0.76–0.97).
Other signiﬁcant factors were baseline comorbidities including
congestive heart failure, hypertension, diabetes, hyperlipidemia;
baseline number of drug therapeutic classes, baseline non-statin
lipid-lowering drug use, age, and year of hospitalization. CON-
CLUSIONS: Fewer than half the patients received statin therapy
after CHD hospitalization. Co-payment appears to be a signiﬁ-
cant barrier to the initiation of statins, even after adjusting for
other demographic and clinical variables.
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Many studies have shown that high serum concentrations of
LDL-C are a major risk factor for coronary heart disease (CHD)
and that lowering LDL-C levels will reduce the risk of major
coronary events. Despite the availability of the National Cho-
lesterol Education Program Adult Treatment Panel III (ATP III)
guidelines for the management of hyperlipidemia, most patients
do not achieve their target LDL goals. OBJECTIVE: To evalu-
ate the impact of clinical pharmacist intervention on LDL-C 
outcomes, in patients at high risk of cardiovascular events.
METHODS: Forty-six patients with clinical atherosclerosis, a
disease that confers high risk for CHD events, under the age of
70 with LDL >110mg/dL were identiﬁed from the data systems
of Maccabi Healthcare Services (study group). The clinical phar-
macist intervention consisted of meeting the physicians in order
to present and discuss information regarding the ATP III recom-
mendations on the management of hyperlipidaemia, and to go
over patients clinical charts. Meetings were followed by written
recommendations regarding LDL management and by periodic
telephone follow-up to ensure implementation of the recom-
mendations. Outcome analysis was based on a comparison
between the study group and a control group (169 patients with
similar characteristics). RESULTS: After 6-months follow-up
81% of the patients in the study group showed an improvement
in LDL levels, with 24% achieving the ATP III goal for high risk
patients of LDL <100mg/dL. In the control group the numbers
were 61% and 16% respectively. CONCLUSION: Results of
several studies evaluating intervention programs indicate that
pharmacists can play a key role in improving cholesterol man-
agement in lipid clinics, community pharmacies, or hospitals.
This study demonstrates for the ﬁrst time in Israel that clinical
pharmacist can have a positive impact on meeting LDL-C goals
and better treatment outcomes.
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OBJECTIVES: This study investigated in French primary care,
the association between LDL-cholesterol goal attainment (LDL-
C < 130mg/dL in national guidelines) during three consecutive
years and occurrence of cardiovascular events (CV) in multiple
CV risk factor (three or more) patients, without coronary heart
disease history. METHODS: A total of 579 patients treated with
lipid lowering drugs (LLD) for three-years and with a yearly doc-
umented LDL-C (2000–2002) were consecutively included by
236 primary care physicians. Patients were classiﬁed into three
groups according to the number of consecutive years they
attained TO: all 3 years (TO+++: n = 145), only part of the time
(TO intermediate: n = 256), and never (TO---: n = 178). CV
risk factors and CV events (angina pectoris, myocardial infarc-
tion, heart failure, stroke, peripheral artery disease) occurring
during the last year of observation, 2002, were retrospectively
collected through computerized medical records (Thales data-
base) and a speciﬁc questionnaire. The risk of occurrence of a
CV events was studied according to TO status. Logistic regres-
sion model was used, to adjust for baseline differences in CV risk
factors. RESULTS: Only 25% of patients reached TO during all
three years. Patients with at least one CV event were 5.5%,
10.5% and 12.9% respectively in the TO+++, TO intermediate
and TO--- groups. Compared to TO+++, signiﬁcantly increased
risk of CV event was observed, both for TO intermediate (OR
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= 2.34, 95% IC = [1.01; 5.39]) and TO--- groups (OR = 2.99,
95% CI = [1.26; 7.08]).The trend in CV risk between the three
TO groups was signiﬁcantly increased (p = 0.02). CONCLU-
SION: This study conﬁrms that inadequate LDL-cholesterol goal
attainment in high CV risk patients treated with LLD is associ-
ated with an increased risk of cardiovascular morbidity. Our
results strongly support the necessity of a better adherence to
guidelines to improve cardiovascular prevention.
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OBJECTIVES: Determine what variables can be used in a phar-
macy claim database to develop a predictive model and to 
identify patients who are likely to be poorly compliant with
statin treatment at the time of the initial statin prescription.
METHODS: The sample includes 22,767 patients over the age
of 18 who were continuously eligible for at least two-years. The
patients are all new statin users as deﬁned by a one-year wash-
out period before the ﬁrst statin prescription. All patients have
one year of data after the ﬁrst statin prescription. Pharmacy
claims in the year before the ﬁrst statin prescription, along with
demographic and health plan information are used to construct
three predictive models, based on three different. METHODS:
1) logistic; 2) classiﬁcation tree; and 3) neural network. Com-
pliance was measured with the medication possession ratio
(MPR), and predictive power was determined with the area
under the receiver operating curve (AUC). Models were created
with an analysis set of 12,767 patients and validated on the
remaining 10,000 patients. Each AUC is computed from the test
sample. RESULTS: The most signiﬁcant predictors are: age less
than 40, having more than 30 total claims, having a large pro-
portion of reﬁll claims (over 60%) as opposed to new prescrip-
tions, using drugs for anxiety and tension, and being treated for
glaucoma. We compared the AUC generated by predicting high
compliance as deﬁned by a MPR greater than 0.8 with each
model. All models demonstrated a similar predictive power, 
with neural networks performing better at predicting high com-
pliance (AUC = 0.62) then classiﬁcation tree (AUC = 0.61) and
logistic regression (AUC = 0.57). CONCLUSION: Despite the
limited predictability of compliance in patients new to statin
treatment, accurate models can be developed using only phar-
macy claims.
CARDIOVASCULAR DISEASE—Hypertension
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OBJECTIVES: Comorbidity often is an important confounder in
health outcomes studies. Although a number of comorbidity
measurements are available, little is known about their perfor-
mance in studies in which health expenditures are the primary
outcome. This study compares the performance of the Elixhauser
Index and Charlson Index as well as remedial measurements of
annual prescription use and physician visits in predicting health
expenditures. METHODS: The study population included
19,793 members of a managed care organization who received
a new prescription for an antihypertensive medication in 2002.
Elixhauser and Charlson scores were derived from hospital
claims occurring in the year preceding this encounter. The sum
of physician’s visits and prescription ﬁlls were calculated simi-
larly. The primary prediction outcome was the log transformed
sum of prescription, physician, and hospital expenditures in the
year following the encounter. Performance was determined by
ﬁtting linear regression models and examining R2 statistics.
RESULTS: A greater proportion of regression model variance
was explained by the Charlson Index (R2 = 0.0989) than the 
Elixhauser Index (R2 = 0.0665). The remedial measurements 
of number of prescriptions ﬁlled (R2 = 0.1413) and number of
physician’s visits (R2 = 0.1295) per year appears better at pre-
dicting future health expenditures than the comorbidity indices
examined. The addition of age and gender to the model increases
the explained proportion of variance for each measurement. The
addition of number of prescriptions, number of physician’s visits,
age, and gender maximizes the explained proportion of variance
for the Charlson Index model (R2 = 0.2526) and Elixhauser
Index model (R2 = 0.2135). CONCLUSION: The Charlson
Index appears to outperform the Elixhauser Index as a comor-
bidity control in health expenditure studies. However, compared
to the remedial measurements of number of prescriptions ﬁlled
and number of physician visits per year these indices appear 
inferior.
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OBJECTIVES: To assess prevalence, awareness, and control of
hypertension in a Latino population in Los Angeles County, CA,
USA. METHODS: Data included 6118 subjects and were
obtained from the Los Angeles Latino Eye Study (LALES), a 
population-based study originally developed to assess the preva-
lence of eye disease and self-reported visual functioning in
Latinos aged 40 or more years. Hypertension history was
reported by participants and blood pressure clinical values were
assessed by two measurements during a clinical exam. Subjects
self-reporting hypertension were deﬁned as aware of their con-
dition and were considered controlled if measured blood pres-
sure values were, on average, lower than 140/90mmHg or
130/80mmHg for diabetics. T-tests and Chi-square tests were
used to test for signiﬁcant differences between groups on demo-
graphic, socioeconomic and access to care variables. RESULTS:
In this population, prevalence of hypertension was 42.4%
(2592/6118). Prevalence was not statistically different between
men and women (p = 0.6773) but increased with age (p <
0.0001). Univariate analyses showed that the percentage of sub-
jects with hypertension also differed signiﬁcantly (p < 0.05) by
obesity status, number of comorbidities, place of birth, marital
and employment statuses, acculturation, education and income
levels, and by access to care variables (usual clinic, doctor and
health insurance). Seventy-two percent of people with hyperten-
sion were aware of it (1855/2592). Awareness was signiﬁcantly
higher among women (76% vs. 64%, p < 0.0001) but increased
with age in men (p < 0.0001). Awareness also varied by number
of comorbidities, place of birth, employment status, and access
to care variables. Finally, only 22% (420/1855) of subjects aware
of having high blood pressure were considered as controlled after
